IPF
Clinical trials for IPF explained in plain language.
Never miss a new study
Get alerted when new IPF trials appear
Sign up with your email to follow new studies for IPF, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to slow lung scarring in IPF patients
Disease control Recruiting nowThis study tests an experimental drug called SB17170 in 30 adults with moderate to severe idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either the drug or a placebo daily for 12 weeks. The main goal is to see if th…
Matched conditions: IPF
Phase: PHASE2 • Sponsor: SPARK Biopharma • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can virtual exercise help lung disease patients breathe easier?
Symptom relief Recruiting nowThis study tests two types of home exercise programs for people with idiopathic pulmonary fibrosis (IPF), a lung disease that makes breathing hard. Participants will be split into two groups: one does live online exercise sessions, the other follows video workouts. The goal is to…
Matched conditions: IPF
Phase: NA • Sponsor: Istanbul Medipol University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Can a breath test predict lung scarring? new study seeks answers
Knowledge-focused Recruiting nowThis observational study aims to find early biomarkers that can predict if a person's lung scarring (pulmonary fibrosis) will get worse quickly. Researchers will follow 450 adults with various types of interstitial lung disease, including IPF and other fibrotic conditions. Partic…
Matched conditions: IPF
Sponsor: Amsterdam UMC, location VUmc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New drug for lung scarring takes first step in healthy volunteers
Knowledge-focused Recruiting nowThis study is an early safety check for a new drug called HW241045, which may one day help treat a lung disease called IPF. Researchers are giving a single dose to 56 healthy adults to see if it is safe and how the body processes it. No treatment benefit is expected for participa…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC